NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

9821	Companies
197095	Keywords
128171	Articles
104822	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 09/11/2025 at 14:30, 4 months 27 days ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. announces participation in LSX World Congress 2025 to present revolutionary broad-spectrum antiviral drug NV-387 and potential impact on viral infections

NanoViricides NV-387 Antiviral Drug Viral Infections LSX World Congress
BRIEF

published on 09/09/2025 at 14:35, 4 months 29 days ago

NanoViricides présentera un médicament antiviral révolutionnaire au congrès LSX

NanoViricides NV-387 Essai Clinique Médicaments Antiviraux Congrès LSX
BRIEF

published on 09/09/2025 at 14:35, 4 months 29 days ago

NanoViricides to Showcase Revolutionary Antiviral Drug at LSX Congress

NanoViricides NV-387 Antiviral Drugs Clinical Trial LSX Congress
PRESS RELEASE

published on 09/09/2025 at 14:30, 4 months 29 days ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
NanoViricides, Inc. to showcase revolutionary antiviral drug NV-387 at LSX World Congress 2025 in Boston. Update on drug pipeline and platform technologies by Dr. Diwan

NanoViricides NV-387 Antiviral Drug LSX World Congress Dr. Diwan
BRIEF

published on 08/18/2025 at 14:35, 5 months 21 days ago

NanoViricides annonce l'essai clinique prometteur du médicament antiviral NV-387

NV-387 Essais Cliniques Inflammation Anti-cancer Médicament Antiviral
BRIEF

published on 08/18/2025 at 14:35, 5 months 21 days ago

NanoViricides Reports Promising Antiviral Drug NV-387 in Clinical Trials

NV-387 Clinical Trials Antiviral Drug Inflammation Anti-cancer
PRESS RELEASE

published on 08/18/2025 at 14:30, 5 months 21 days ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
NanoViricides, Inc. reports NV-387 antiviral drug could reduce metastatic cancer resurgence caused by viral infections. NV-387 completed Phase I trial, advancing to Phase II

NV-387 NanoViricides Inc. Antiviral Drug Viral Infections Metastatic Cancer
BRIEF

published on 07/30/2025 at 14:35, 6 months 9 days ago

NanoViricides présente le NV-387 comme une solution clé contre la rougeole face à l'augmentation des cas

Désignation De Médicament Orphelin Médicament NV-387 Augmentation De La Rougeole Vaccination Mondiale Risque Pour La Santé Publique
BRIEF

published on 07/30/2025 at 14:35, 6 months 9 days ago

NanoViricides Highlights NV-387 as Key Measles Solution Amid Rising Cases

Orphan Drug Designation NV-387 Drug Measles Increase Global Vaccination Public Health Risk
PRESS RELEASE

published on 07/30/2025 at 14:30, 6 months 9 days ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
NanoViricides introduces drug candidate NV-387 as a potential treatment for Measles outbreak. The drug has shown safety and effectiveness in animal studies and Phase I trial, aiming to combat the global epidemic

NanoViricides NV-387 Antiviral Vaccination Measles

Accesswire

Published on 02/07/2026 at 01:00, 1 day 20 hours ago

Green Bridge Metals Can Help Secure U.S. Production of Critical Mineral Titanium
Published on 02/06/2026 at 23:10, 1 day 21 hours ago

Topline Capital Management, LLC Announces Disposition of Shares of NamSys Inc.
Published on 02/06/2026 at 22:01, 1 day 22 hours ago

Totec Resources Announces Listing of Shares on the Frankfurt Stock Exchange and Adoption of Omnibus Incentive Plan
Published on 02/06/2026 at 15:30, 2 days 5 hours ago

Vulcan Minerals Inc. - Drilling Program Update for the Carbonear Zinc-Lead SEDEX project in Newfoundland
Published on 02/06/2026 at 13:30, 2 days 7 hours ago

Redwood AI Corp. (formerly Marshall Technologies Corp.) Announces Closing of IPO and Listing of Shares on the Canadian Securities Exchange

View all ACCESSWIRE

EQS Group

Published on 02/07/2026 at 21:00, 23 hours 59 minutes ago

Alibaba Group Debuts 'Wonder on Ice,' an Immersive AI Experience at Milan’s Sforza Castle for Milano Cortina 2026
Published on 02/07/2026 at 16:35, 1 day 4 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies
Published on 02/07/2026 at 16:20, 1 day 4 hours ago

NOTICE OF SETTLEMENT APPROVAL HEARING - SHORT FORM - WAYLAND GROUP CORP., SCOTT LANGILLE, GERHARD MÜLLER, PAUL PATHAK, ERIC SILVER, MICHAEL STEIN, JOHN DOES 1-3, CANACCORD GENUITY CORP., AND RF SECURITIES CLEARING LP (FORMERLY KNOWN AS GMP SECU
Published on 02/06/2026 at 19:25, 2 days 1 hour ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/06/2026 at 17:52, 2 days 3 hours ago

EQS-Adhoc: Avemio AG: Preparation of the filing for insolvency proceedings by Teltec AG, a subsidiary of Avemio AG, and potential effects on the going-concern assessment of Avemio AG

Les Echos

Published on 02/06/2026 at 18:22, 2 days 2 hours ago

Déclaration du nombre d’actions et droits de vote au 31 janvier 2026
Published on 02/06/2026 at 18:22, 2 days 2 hours ago

Disclosure of Share Capital and Voting Rights as of January 31, 2026
Published on 02/06/2026 at 16:01, 2 days 4 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010093328
Published on 02/06/2026 at 16:01, 2 days 4 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010093328
Published on 02/06/2026 at 07:54, 2 days 13 hours ago

ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 janvier 2026

View all LES ECHOS COMFI WIRE